What Innorna Co. Ltd does

Innorna Co. Ltd is a clinical-stage biotechnology company founded in 2019 and headquartered in Hong Kong that engineers mRNA-based medicines delivered via its proprietary lipid nanoparticle (LNP) platform. The company is organized around three vertically integrated platform pillars: a Diversity-Oriented LNP delivery system built on a chemically diverse ionizable lipid library of 6,000+ synthesized lipids drawn from 100,000+ rationally designed structures, including a targeted LNP platform that combines antibody engineering with optimized conjugation chemistry for cell-type-specific delivery; advanced mRNA engineering capabilities comprising proprietary UTR libraries, codon optimization algorithms, poly(A) tail engineering, and capping chemistry; and fully in-house cGMP manufacturing spanning lipid synthesis, mRNA production, LNP formulation, and drug product fill-finish across six integrated sites in China, the US, and Europe.

The clinical pipeline addresses three therapeutic areas: chronic metabolic disease (IN026, an mRNA therapy delivering urate oxidase for refractory gout, FDA IND cleared March 2026), in vivo immunotherapy for autoimmune disease (IN036 for systemic lupus erythematosus), and infectious disease vaccines (IN006 bivalent RSV vaccine — China's first non-COVID-19 mRNA vaccine approval; IN001 herpes zoster; IN023 HSV-2; IN029 RSV/hMPV combination). Four protein replacement therapies have received FDA Rare Pediatric Disease and Orphan Drug Designations. The company has dosed over 900 study participants across clinical programs and is recognized through Forbes China Industry Leaders, MIT Technology Review 50 Smartest Companies, and Fortune China Impact Startups awards.

Innorna operates a partnership-led business model rather than direct commercialization, monetizing its platform through platform out-licensing, co-development, and asset out-licensing arrangements that generate upfront cash, development/regulatory/commercial milestones, and tiered royalties. The flagship counterparty is BeiGene, which under a July 2022 worldwide strategic collaboration holds exclusive global development and commercialization rights for jointly discovered mRNA-LNP programs and a non-exclusive license to Innorna's LNP technology. Additional partners include Zhifei Biotech (vaccine commercialization in China) and PATH (global health access), with US clinical and operations presence in Boston and San Diego and European clinical operations in Berlin. To date Innorna has raised approximately $150 million across angel, Series A, and $120 million Series B rounds and is privately held.

Name

Innorna Co. Ltd

Legal name

Innorna Co., Ltd.

Website

https://innorna.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Innorna is a clinical-stage biotechnology company developing mRNA-based therapeutics and vaccines delivered via its proprietary lipid nanoparticle platform, serving patients with chronic metabolic disease, autoimmune conditions, and infectious diseases through strategic partnerships.

Ownership category

akta.pro rank

Product category

mRNA Therapeutics & Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• MRNA therapeutics platform
• Lipid nanoparticle delivery
• Clinical-stage biotechnology
• Nucleic acid drug development
• CGMP biopharmaceutical manufacturing

Headquarters

HQ city

Hong Kong

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Strategic Partnerships and Collaborations: Innorna receives upfront cash payments, development, regulatory, and commercial milestone payments, as well as tiered royalties from partnership programs. Example: BeiGene collaboration where Innorna received upfront payment and is eligible for additional payments based on milestone achievements plus royalties.
2. Platform Licensing: Non-exclusive license to proprietary LNP Technology granted to partners for their internal research efforts, generating upfront and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Innorna develops and clinically advances mRNA-based medicines built on its proprietary lipid nanoparticle (LNP) delivery platform. The company internally designs and synthesizes chemically diverse ionizable lipids, engineers mRNA payloads, and operates fully integrated cGMP manufacturing to produce drug candidates for chronic metabolic diseases (e.g., IN026 for refractory gout), in vivo immunotherapies for autoimmune conditions (e.g., IN036 for systemic lupus erythematosus), and infectious disease vaccines (e.g., IN006 bivalent RSV, IN001 herpes zoster). The business monetizes these assets through platform out-licensing, co-development, and asset out-licensing arrangements with pharmaceutical and biotechnology partners.

Product overview

Innorna is a clinical-stage biotechnology company that has built a proprietary, vertically integrated mRNA-LNP platform for developing RNA medicines. The company's product portfolio consists of mRNA-based therapeutics and vaccines organized across three therapeutic areas: chronic disease (IN026 for refractory gout), in vivo immunotherapy (IN036 for autoimmune diseases), and infectious disease vaccines (IN006 for RSV, IN001 for herpes zoster, IN023 for HSV-2, IN029 for RSV/hMPV combo). Supporting the pipeline are three core platform technologies—LNP Delivery (with over 6,000 ionizable lipids), mRNA Engineering, and CMC Manufacturing—all fully integrated from discovery through cGMP production. The company operates 6 vertically integrated R&D to cGMP manufacturing sites and has 3 drug candidates in clinic with over 900 study participants dosed.

Differentiator

Problem solved

Functional benefit

Products and services

• IN026 (refractory gout mRNA therapy) Investigational mRNA-based therapy for refractory gout that delivers mRNA encoding urate oxidase to the liver for systemic uric acid breakdown, engineered on Innorna's proprietary mRNA-LNP platform for repeat administration and long-term disease control. Targeted at patients with refractory gout (approximately 3% of all gout patients, ~1.9 million worldwide) who have limited treatment options.
• IN036 (SLE / autoimmune mRNA therapy) Clinical-stage mRNA drug candidate for systemic lupus erythematosus (SLE) with potential application in other autoimmune diseases, developed as part of Innorna's in vivo immunotherapy pipeline using targeted LNP delivery to immune cells.
• IN006 (bivalent RSV mRNA vaccine) World's first bivalent RSV mRNA vaccine targeting RSV-A and RSV-B subtypes, built on Innorna's proprietary pre-fusion F protein design, mRNA, and LNP platforms. China's first non-COVID-19 mRNA vaccine and first domestically developed RSV vaccine to enter clinical trials.
• IN001 (Herpes Zoster mRNA vaccine) Herpes Zoster (HZ) mRNA vaccine candidate developed using Innorna's mRNA-LNP platform; received FDA IND clearance (September 2023) enabling Phase I initiation and China IND clearance (July 2024).
• IN023 (HSV-2 mRNA vaccine candidate) Herpes Simplex Virus Type 2 (HSV-2) mRNA vaccine candidate in development at Innorna using its proprietary mRNA-LNP platform.
• IN029 (RSV/hMPV combination vaccine candidate) RSV/hMPV combination vaccine candidate for prevention of combined respiratory syncytial virus and human metapneumovirus infection, developed on Innorna's mRNA-LNP platform.
• INH002 (undisclosed pipeline asset) Undisclosed pipeline asset in Innorna's development portfolio.
• LNP Delivery Platform Proprietary Diversity-Oriented lipid nanoparticle (LNP) delivery platform for delivering mRNA safely and effectively into target cells, built on a chemically diverse ionizable lipid library of over 6,000 synthesized lipids screened from more than 100,000 rationally designed structures. Includes targeted LNP capability combining antibody engineering with optimized conjugation chemistry for cell-type-specific delivery. Licensed and co-developed with pharmaceutical and biotechnology partners.
• mRNA Engineering Platform Proprietary mRNA engineering platform comprising UTR libraries for enhanced translational efficiency, codon optimization algorithms, poly(A) tail engineering, and capping chemistry for high translational fidelity and tolerability. Each mRNA payload is purpose-built for its therapeutic context. Offered to partners through platform licensing and co-development arrangements.

Quantifiable outcome

• 900+ study participants dosed across clinical programs validating platform safety and efficacy
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• BeiGeneflagshipStrategic or Co-development Partner · 6 July 2022Worldwide strategic collaboration to jointly discover mRNA-LNP programs. BeiGene holds exclusive global development and commercialization rights for product candidates from the programs. Innorna received upfront cash payment and is eligible for additional payments based on achievement of development, regulatory, and commercial milestones, as well as tiered royalties. BeiGene also gains non-exclusive license to Innorna's proprietary LNP Technology for internal discovery efforts.
• BeOne MedicinescoreStrategic or Co-development PartnerStrategic partnership to accelerate development and commercialization of Innorna's mRNA pipeline. Partnership aimed at leveraging combined expertise in mRNA therapeutics development.
• ZhiFei Biotech (ZFSW)coreStrategic or Co-development PartnerTechnical cooperation with Shenxin Biotechnology targeting mRNA R&D projects. Zhifei Biotech is a leading vaccine company in China with strong commercialization capabilities.
• PATHminorStrategic or Co-development PartnerExploratory collaboration to develop innovative mRNA vaccine technologies aiming to make such innovations more widely accessible, particularly for global health applications.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CureVac: Clinical-stage mRNA company developing prophylactic vaccines and protein-replacement therapeutics using mRNA and LNP delivery. Comparable in clinical stage, technology focus, and platform-licensing business model.
• BioNTech: Commercial-stage mRNA company with Comirnaty (Pfizer-partnered COVID vaccine) and a deep pipeline in oncology, infectious disease, and protein-replacement therapies. Closely comparable to Innorna on mRNA-LNP platform technology and therapeutic-area breadth.
• Moderna: Global mRNA platform leader with approved Spikevax COVID vaccine and a broad pipeline spanning oncology, rare disease, and infectious disease vaccines. Directly comparable to Innorna as an mRNA-LNP platform play targeting protein-replacement and vaccine applications.
• Abogen Biosciences: China-based mRNA therapeutics developer with COVID vaccine approvals and an expanding pipeline in oncology and infectious disease. Comparable to Innorna as a Chinese mRNA platform peer advancing into non-COVID indications.
• Stemirna Therapeutics: China-based clinical-stage mRNA therapeutics company with a similar LNP platform focus and pipeline spanning infectious disease vaccines and protein-replacement therapies. A close direct comparable given shared China mRNA ecosystem, similar stage, and licensing-driven model.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery and self-amplifying RNA technology, partnered with CSL Seqirus for vaccines. Directly comparable to Innorna on platform technology, pipeline stage, and licensing model.

Others

• Genevant Sciences: Lipid nanoparticle delivery technology company developing both internal and partnered RNA therapeutics programs. Comparable to Innorna's LNP platform business model and chemistry focus but structured around out-licensing rather than wholly owned pipeline development.
• Acuitas Therapeutics: LNP delivery technology specialist that supplies ionizable lipids to multiple mRNA partners including Pfizer/BioNTech. Comparable to Innorna on LNP chemistry IP but operates as a platform/enabler rather than a clinical developer.

Regional players

• ZhiFei Biological Products (ZFSW): Leading China vaccine company with strong commercialization capabilities across infectious disease vaccines and an active partner of Innorna on mRNA R&D. Comparable as a China-focused vaccine commercialization counterpart rather than a direct technology competitor.

Broad incumbents

• CSL Seqirus: Global vaccine leader (CSL subsidiary) that partnered with Arcturus for an approved mRNA COVID vaccine (Kostaive) and is expanding into broader mRNA applications. Comparable to Innorna as an established global vaccine player adopting mRNA-LNP technology.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/innorna

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innorna Co. Ltd